The clinical analysis of 6374 patients with hyperthyroidism by radiopharmaceuticals 131I therapy / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
;
(12): 2947-2948, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-436680
ABSTRACT
Objective To probe into optimal delivered dose of 131I therapy in hyperthyroidism and influencing factors.Methods Data of 6374 patients with hyperthyroidism receiving 131I therapy were summarized and analyzed.The patients were differentiated into Graves group (GD) and multinodular toxic goiter group (NGD) after 131I therapy.To compare incidence of hypothyroidism between two groups after 131I therapy,partial correlations analysis was performed between delivered dose and other variables influencing factors among cured patients.Results After 131I therapy incidence of permanently hypothyroidismin patients with Graves' group was much higher than that in patients with multinodular toxic goiter group(17.01%,0.39%,Pearson x2 value =704.8,P < 0.01).Delivered dose of 131I therapy related closely to thyroid size,with or without nodules and thyroid rigidity(r =0.469,0.484,0.553).Disposable cured rate of 131I therapy was higher than 63.99%.Conclusion 131I therapy is optimal to multinodular toxic goiter.Delivered dose of 131I therapy will be increased for patients with bigger and stiff mass for therapeutic effects.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Primary Medicine and Pharmacy
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS